Katarina Sjögreen Gleisner1, Gustav Brolin2, Anna Sundlöv3, Edita Mjekiqi4, Karl Östlund5, Jan Tennvall3, Erik Larsson2. 1. Department of Clinical Sciences Lund, Medical Radiation Physics, Lund University, Lund, Sweden katarina.sjogreen_gleisner@med.lu.se. 2. Department of Clinical Sciences Lund, Medical Radiation Physics, Lund University, Lund, Sweden. 3. Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. 4. Department of Clinical Sciences Lund, Medical Radiation Physics, Lund University, Lund, Sweden ZERNIKE Institute for Advanced Materials, University of Groningen, Groningen, The Netherlands; and. 5. Department of Translational Medicine, Lund University, Lund, Sweden.
Abstract
UNLABELLED: Dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the long-term activity retention follows the pattern determined from the first week. This work aimed to investigate the validity of this assumption by performing additional patient measurements between 5 and 10 wk after administration. A further aim was to investigate to what extent absorbed dose values were affected when including these measurements, also taking into account the radionuclide impurity of (177m)Lu and build-up of secondary (177)Lu from the (177m)Lu decay. METHODS: A combination of methods was used: planar γ-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body activity between 5 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10 wk after injection for assessment of the activity distribution. From these measurements the long-term retention of activity was determined and the relative influence on absorbed doses calculated. RESULTS: The most important finding was a clearly visualized tumor uptake in images from between 5 and 7 wk after injection and in 1 patient also kidney and spleen uptake in images acquired on day 33. As a consequence, the total-body time-activity curve had a tail, which was not completely captured by imaging during the first week. The absorbed doses to total body and tumors obtained when including these late time points were on average 5%-6% higher than those obtained when using data acquired during the first week. The contributions to the absorbed dose from (177m)Lu and secondary (177)Lu were negligible. CONCLUSION: At approximately 5-7 wk after injection, there was a measureable amount of (177)Lu-DOTATATE in patients, which is mainly governed by retention in tumors. For tumor dosimetry, imaging at a later time than the routinely used 7 d may be warranted. The contribution to the absorbed dose from the radionuclide impurity of (177m)Lu was negligible.
UNLABELLED: Dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE is based on patient imaging during the first week after administration and determination of the activity retention as a function of time for different tissues. For calculation of the absorbed dose, it is generally assumed that the long-term activity retention follows the pattern determined from the first week. This work aimed to investigate the validity of this assumption by performing additional patient measurements between 5 and 10 wk after administration. A further aim was to investigate to what extent absorbed dose values were affected when including these measurements, also taking into account the radionuclide impurity of (177m)Lu and build-up of secondary (177)Lu from the (177m)Lu decay. METHODS: A combination of methods was used: planar γ-camera imaging as part of the clinical dosimetry protocol, determination of the whole-body activity between 5 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10 wk after injection for assessment of the activity distribution. From these measurements the long-term retention of activity was determined and the relative influence on absorbed doses calculated. RESULTS: The most important finding was a clearly visualized tumor uptake in images from between 5 and 7 wk after injection and in 1 patient also kidney and spleen uptake in images acquired on day 33. As a consequence, the total-body time-activity curve had a tail, which was not completely captured by imaging during the first week. The absorbed doses to total body and tumors obtained when including these late time points were on average 5%-6% higher than those obtained when using data acquired during the first week. The contributions to the absorbed dose from (177m)Lu and secondary (177)Lu were negligible. CONCLUSION: At approximately 5-7 wk after injection, there was a measureable amount of (177)Lu-DOTATATE in patients, which is mainly governed by retention in tumors. For tumor dosimetry, imaging at a later time than the routinely used 7 d may be warranted. The contribution to the absorbed dose from the radionuclide impurity of (177m)Lu was negligible.
Authors: Carlos F Uribe; Pedro L Esquinas; Jesse Tanguay; Marjorie Gonzalez; Emilie Gaudin; Jean-Mathieu Beauregard; Anna Celler Journal: EJNMMI Phys Date: 2017-01-07
Authors: Daphne Merel Valerie Huizing; Berlinda Jantina de Wit-van der Veen; Marcel Verheij; Marcellus Petrus Maria Stokkel Journal: EJNMMI Res Date: 2018-08-29 Impact factor: 3.138
Authors: Anna Sundlöv; Johan Gustafsson; Gustav Brolin; Nadja Mortensen; Rebecca Hermann; Peter Bernhardt; Johanna Svensson; Michael Ljungberg; Jan Tennvall; Katarina Sjögreen Gleisner Journal: EJNMMI Phys Date: 2018-07-05
Authors: Katarina Sjögreen Gleisner; Nicolas Chouin; Pablo Minguez Gabina; Francesco Cicone; Silvano Gnesin; Caroline Stokke; Mark Konijnenberg; Marta Cremonesi; Frederik A Verburg; Peter Bernhardt; Uta Eberlein; Jonathan Gear Journal: Eur J Nucl Med Mol Imaging Date: 2022-03-14 Impact factor: 10.057
Authors: Daphne M V Huizing; Michiel Sinaasappel; Marien C Dekker; Marcel P M Stokkel; Berlinda J de Wit-van der Veen Journal: J Appl Clin Med Phys Date: 2020-08-13 Impact factor: 2.102